The results of DAPA-HF and the beneficial effects of dapagliflozin in nondiabetic patients with HF were proven and reinforced by the study on SGLT-2 inhibitors, as was their therapeutic role in other cardiometabolic conditions, apart from their already-known positive glycemic effects in type 2 DM [140]. Here, SLC5A2 is linked to hydrops fetalis.